Toward understanding Machado-Joseph disease.

Human pluripotent stem cells: applications and challenges in neurological diseases. Front Physiol (2012) 1.31

Consensus paper: pathological mechanisms underlying neurodegeneration in spinocerebellar ataxias. Cerebellum (2014) 1.03

An optimal ubiquitin-proteasome pathway in the nervous system: the role of deubiquitinating enzymes. Front Mol Neurosci (2014) 1.01

ss-siRNAs allele selectively inhibit ataxin-3 expression: multiple mechanisms for an alternative gene silencing strategy. Nucleic Acids Res (2013) 0.99

Allele-selective inhibition of mutant atrophin-1 expression by duplex and single-stranded RNAs. Biochemistry (2014) 0.96

Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice. Mol Ther (2013) 0.94

RNA duplexes with abasic substitutions are potent and allele-selective inhibitors of huntingtin and ataxin-3 expression. Nucleic Acids Res (2013) 0.94

Allele-selective inhibition of expression of huntingtin and ataxin-3 by RNA duplexes containing unlocked nucleic acid substitutions. Biochemistry (2013) 0.93

Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease. Mol Ther (2013) 0.91

Ubiquitin-binding site 2 of ataxin-3 prevents its proteasomal degradation by interacting with Rad23. Nat Commun (2014) 0.90

Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease. Neurotherapeutics (2014) 0.90

Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells. Acta Pharmacol Sin (2013) 0.89

Trinucleotide repeats: a structural perspective. Front Neurol (2013) 0.89

Ubiquitination regulates the neuroprotective function of the deubiquitinase ataxin-3 in vivo. J Biol Chem (2013) 0.88

Genetic counseling and presymptomatic testing programs for Machado-Joseph Disease: lessons from Brazil and Portugal. Genet Mol Biol (2014) 0.88

JosD1, a membrane-targeted deubiquitinating enzyme, is activated by ubiquitination and regulates membrane dynamics, cell motility, and endocytosis. J Biol Chem (2013) 0.85

Inactivation of PNKP by mutant ATXN3 triggers apoptosis by activating the DNA damage-response pathway in SCA3. PLoS Genet (2015) 0.85

Using membrane-targeted green fluorescent protein to monitor neurotoxic protein-dependent degeneration of Drosophila eyes. J Neurosci Res (2014) 0.83

The deubiquitinase ataxin-3 requires Rad23 and DnaJ-1 for its neuroprotective role in Drosophila melanogaster. Neurobiol Dis (2015) 0.82

The de-ubiquitinating enzyme ataxin-3 does not modulate disease progression in a knock-in mouse model of Huntington disease. J Huntingtons Dis (2013) 0.81

Examination of Ataxin-3 (atx-3) Aggregation by Structural Mass Spectrometry Techniques: A Rationale for Expedited Aggregation upon Polyglutamine (polyQ) Expansion. Mol Cell Proteomics (2015) 0.81

Two novel SNPs in ATXN3 3' UTR may decrease age at onset of SCA3/MJD in Chinese patients. PLoS One (2015) 0.80

Neurodegenerative diseases in a dish: the promise of iPSC technology in disease modeling and therapeutic discovery. Neurol Sci (2014) 0.80

Characterization of the conformational fluctuations in the Josephin domain of ataxin-3. Biophys J (2014) 0.79

Deubiquitinases (DUBs) and DUB inhibitors: a patent review. Expert Opin Ther Pat (2015) 0.79

A tale of a tail: Structural insights into the conformational properties of the polyglutamine protein ataxin-3. Int J Mass Spectrom (2013) 0.78

RNA-binding protein misregulation in microsatellite expansion disorders. Adv Exp Med Biol (2014) 0.77

Epidemiological, clinical, and molecular characterization of Cuban families with spinocerebellar ataxia type 3/Machado-Joseph disease. Cerebellum Ataxias (2015) 0.77

Atxn2 Knockout and CAG42-Knock-in Cerebellum Shows Similarly Dysregulated Expression in Calcium Homeostasis Pathway. Cerebellum (2017) 0.77

Far-infrared radiation protects viability in a cell model of Spinocerebellar Ataxia by preventing polyQ protein accumulation and improving mitochondrial function. Sci Rep (2016) 0.77

Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models. Mol Ther Nucleic Acids (2017) 0.75

Compound heterozygous intermediate MJD alleles cause cerebellar ataxia with sensory neuropathy. Neurol Genet (2016) 0.75

Alleviating neurodegeneration in Drosophila models of PolyQ diseases. Cerebellum Ataxias (2014) 0.75

CAG repeat length does not associate with the rate of cerebellar degeneration in spinocerebellar ataxia type 3. Neuroimage Clin (2016) 0.75

The 2.2-Angstrom resolution crystal structure of the carboxy-terminal region of ataxin-3. FEBS Open Bio (2016) 0.75

Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders. Mol Neurobiol (2016) 0.75

Structure prediction of polyglutamine disease proteins: comparison of methods. BMC Bioinformatics (2014) 0.75

Patterns of motor signs in spinocerebellar ataxia type 3 at the start of follow-up in a reference unit. Cerebellum Ataxias (2016) 0.75

RNA toxicity and foci formation in microsatellite expansion diseases. Curr Opin Genet Dev (2017) 0.75

The Machado-Joseph Disease Deubiquitinase Ataxin-3 Regulates the Stability and Apoptotic Function of p53. PLoS Biol (2016) 0.75

Transgenic Monkey Model of the Polyglutamine Diseases Recapitulating Progressive Neurological Symptoms. eNeuro (2017) 0.75

Polyglutamine spinocerebellar ataxias - from genes to potential treatments. Nat Rev Neurosci (2017) 0.75

The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev (2002) 16.10

Defining the human deubiquitinating enzyme interaction landscape. Cell (2009) 11.39

Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature (1991) 9.89

CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet (1994) 7.07

Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet (1999) 4.93

Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell (1998) 4.07

Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol (2004) 3.83

Amyloid fibers are water-filled nanotubes. Proc Natl Acad Sci U S A (2002) 3.78

Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron (1997) 3.73

Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature (2008) 3.68

Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet (2005) 3.45

RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature (2008) 2.74

Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci (2008) 2.63

Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J Cell Biol (1998) 2.37

Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol (2009) 2.36

A toxic monomeric conformer of the polyglutamine protein. Nat Struct Mol Biol (2007) 2.33

Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem (1998) 2.23

The gene for Machado-Joseph disease maps to human chromosome 14q. Nat Genet (1993) 2.18

The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Hum Mol Genet (2003) 2.13

Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat Genet (1996) 2.09

The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains. J Biol Chem (2008) 2.09

Chromosomal assignment of the second locus for autosomal dominant cerebellar ataxia (SCA2) to chromosome 12q23-24.1. Nat Genet (1993) 2.03

Regulation of retrotranslocation by p97-associated deubiquitinating enzyme ataxin-3. J Cell Biol (2006) 2.00

Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum Mol Genet (1999) 1.95

Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. J Neurosci (1999) 1.93

Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1. J Biol Chem (2008) 1.92

Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. J Biol Chem (2005) 1.88

Mutations in American families with spinocerebellar ataxia (SCA) type 3: SCA3 is allelic to Machado-Joseph disease. Neurology (1996) 1.87

CAG repeat disorder models and human neuropathology: similarities and differences. Acta Neuropathol (2007) 1.86

Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol Cell (2005) 1.84

Ubiquitin-mediated sequestration of normal cellular proteins into polyglutamine aggregates. Proc Natl Acad Sci U S A (2003) 1.82

Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann Neurol (1996) 1.77

Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. J Biol Chem (2008) 1.69

Ataxin-3 interactions with rad23 and valosin-containing protein and its associations with ubiquitin chains and the proteasome are consistent with a role in ubiquitin-mediated proteolysis. Mol Cell Biol (2003) 1.68

Correlation between CAG repeat length and clinical features in Machado-Joseph disease. Am J Hum Genet (1995) 1.67

Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation. Neurobiol Dis (2008) 1.66

Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3. Brain (2009) 1.66

Autosomal dominant system degeneration in Portuguese families of the Azores Islands. A new genetic disorder involving cerebellar, pyramidal, extrapyramidal and spinal cord motor functions. Neurology (1978) 1.66

Genome-wide screen for modifiers of ataxin-3 neurodegeneration in Drosophila. PLoS Genet (2007) 1.66

The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step. J Biol Chem (2006) 1.66

Ataxin-3 binds VCP/p97 and regulates retrotranslocation of ERAD substrates. Hum Mol Genet (2006) 1.66

The solution structure of the Josephin domain of ataxin-3: structural determinants for molecular recognition. Proc Natl Acad Sci U S A (2005) 1.62

Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J Biol Chem (2003) 1.60

The polyglutamine neurodegenerative protein ataxin 3 regulates aggresome formation. Proc Natl Acad Sci U S A (2005) 1.60

Molecular clearance of ataxin-3 is regulated by a mammalian E4. EMBO J (2004) 1.57

New model for crystalline polyglutamine assemblies and their connection with amyloid fibrils. Biomacromolecules (2005) 1.55

Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain. Ann Neurol (1997) 1.55

The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J Neurochem (2009) 1.52

When more is less: pathogenesis of glutamine repeat neurodegenerative diseases. Neuron (1995) 1.49

Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis. Proc Natl Acad Sci U S A (2002) 1.48

YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. Hum Mol Genet (2002) 1.48

Machado-Joseph disease: an autosomal dominant motor system degeneration. Mov Disord (1992) 1.46

Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3. J Neurosci (2011) 1.46

Deubiquitinating function of ataxin-3: insights from the solution structure of the Josephin domain. Proc Natl Acad Sci U S A (2005) 1.46

Ubiquitination directly enhances activity of the deubiquitinating enzyme ataxin-3. EMBO J (2009) 1.46

A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. J Neurosci (2004) 1.45

An arginine/lysine-rich motif is crucial for VCP/p97-mediated modulation of ataxin-3 fibrillogenesis. EMBO J (2006) 1.45

Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways. J Biol Chem (2003) 1.44

Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. J Neurosci (2008) 1.44

Molecular features of the CAG repeats and clinical manifestation of Machado-Joseph disease. Hum Mol Genet (1995) 1.44

Protein aggregation and the ubiquitin proteasome pathway: gaining the UPPer hand on neurodegeneration. Curr Opin Genet Dev (2003) 1.41

Epidemiology and clinical aspects of Machado-Joseph disease. Adv Neurol (1993) 1.41

Ataxin-3, the MJD1 gene product, interacts with the two human homologs of yeast DNA repair protein RAD23, HHR23A and HHR23B. Hum Mol Genet (2000) 1.38

Ube2w and ataxin-3 coordinately regulate the ubiquitin ligase CHIP. Mol Cell (2011) 1.37

Evidence for inter-generational instability in the CAG repeat in the MJD1 gene and for conserved haplotypes at flanking markers amongst Japanese and Caucasian subjects with Machado-Joseph disease. Hum Mol Genet (1995) 1.36

Elucidation of ataxin-3 and ataxin-7 function by integrative bioinformatics. Hum Mol Genet (2003) 1.36

Defining the role of ubiquitin-interacting motifs in the polyglutamine disease protein, ataxin-3. J Biol Chem (2005) 1.34

Therapeutics development for triplet repeat expansion diseases. Nat Rev Genet (2005) 1.34

Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS One (2008) 1.34

Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence. J Neurosci (2007) 1.34

SCA3: neurological features, pathogenesis and animal models. Cerebellum (2008) 1.31

Mechanisms of ataxin-3 misfolding and fibril formation: kinetic analysis of a disease-associated polyglutamine protein. J Mol Biol (2007) 1.29

Polyglutamine diseases and transport problems: deadly traffic jams on neuronal highways. Arch Neurol (2005) 1.28

The UBL domain of PLIC-1 regulates aggresome formation. EMBO Rep (2006) 1.27

Clinical criteria for diagnosis of Machado-Joseph disease: report of a non-Azorena Portuguese family. Neurology (1980) 1.27

Autosomal dominant striatonigral degeneration. A clinical, pathologic, and biochemical study of a new genetic disorder. Neurology (1976) 1.27

Dominantly inherited ataxias: lessons learned from Machado-Joseph disease/spinocerebellar ataxia type 3. Semin Neurol (2007) 1.25

The ubiquitination code: a signalling problem. Cell Div (2007) 1.25

Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination. Biochem Biophys Res Commun (2007) 1.24

Nigro-spino-dentatal degeneration with nuclear ophthalmoplegia. A unique and partially treatable clinico-pathological entity. J Neurol Sci (1972) 1.23

Autosomal dominant cerebellar ataxia type I. MRI-based volumetry of posterior fossa structures and basal ganglia in spinocerebellar ataxia types 1, 2 and 3. Brain (1998) 1.23

Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities. J Biol Chem (2002) 1.21

The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability. Hum Mol Genet (2010) 1.21

Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation. J Neurosci (2006) 1.19

Machado-Joseph Disease: from first descriptions to new perspectives. Orphanet J Rare Dis (2011) 1.18

Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3. Hum Mol Genet (2006) 1.18

Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease. Brain (2011) 1.17

Balancing act: deubiquitinating enzymes in the nervous system. Trends Neurosci (2011) 1.17

Josephin domain of ataxin-3 contains two distinct ubiquitin-binding sites. Biopolymers (2009) 1.17

An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. Brain Pathol (1998) 1.17

Domain architecture of the polyglutamine protein ataxin-3: a globular domain followed by a flexible tail. FEBS Lett (2003) 1.16

Molecular and clinical correlations in spinocerebellar ataxia type 3 and Machado-Joseph disease. Ann Neurol (1995) 1.15

Cellular turnover of the polyglutamine disease protein ataxin-3 is regulated by its catalytic activity. J Biol Chem (2007) 1.14

Functional interactions as a survival strategy against abnormal aggregation. FASEB J (2010) 1.13

Accumulation of NEDD8 in neuronal and glial inclusions of neurodegenerative disorders. Neuropathol Appl Neurobiol (2005) 1.13

Activity and cellular functions of the deubiquitinating enzyme and polyglutamine disease protein ataxin-3 are regulated by ubiquitination at lysine 117. J Biol Chem (2010) 1.12

Gp78, an ER associated E3, promotes SOD1 and ataxin-3 degradation. Hum Mol Genet (2009) 1.11

Small heat-shock proteins interact with a flanking domain to suppress polyglutamine aggregation. Proc Natl Acad Sci U S A (2010) 1.11

Inhibition of Rho kinases enhances the degradation of mutant huntingtin. J Biol Chem (2009) 1.10

Machado-Joseph disease: A proposal of spastic paraplegic subtype. Neurology (1996) 1.08

siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol (2002) 5.65

RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A (2005) 4.79

RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med (2004) 4.63

Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci U S A (2003) 3.00

CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome. Neuron (2013) 2.94

Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci (2008) 2.63

RNA-mediated neurodegeneration in repeat expansion disorders. Ann Neurol (2010) 2.30

The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains. J Biol Chem (2008) 2.09

Brain structure in preclinical Huntington's disease. Biol Psychiatry (2005) 2.05

Early autophagic response in a novel knock-in model of Huntington disease. Hum Mol Genet (2010) 1.99

Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol Cell (2005) 1.84

Aberrant cellular behavior of mutant torsinA implicates nuclear envelope dysfunction in DYT1 dystonia. J Neurosci (2004) 1.71

CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo. J Neurosci (2005) 1.57

Silencing primary dystonia: lentiviral-mediated RNA interference therapy for DYT1 dystonia. J Neurosci (2005) 1.53

Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis. Proc Natl Acad Sci U S A (2002) 1.48

Spinocerebellar ataxias: an update. Curr Opin Neurol (2007) 1.48

Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3. J Neurosci (2011) 1.46

Ubiquitination directly enhances activity of the deubiquitinating enzyme ataxin-3. EMBO J (2009) 1.46

Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways. J Biol Chem (2003) 1.44

Protein aggregation and the ubiquitin proteasome pathway: gaining the UPPer hand on neurodegeneration. Curr Opin Genet Dev (2003) 1.41

Ube2w and ataxin-3 coordinately regulate the ubiquitin ligase CHIP. Mol Cell (2011) 1.37

Defining the role of ubiquitin-interacting motifs in the polyglutamine disease protein, ataxin-3. J Biol Chem (2005) 1.34

In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis. Neurobiol Dis (2008) 1.28

Genome-wide DNA methylation differences between late-onset Alzheimer's disease and cognitively normal controls in human frontal cortex. J Alzheimers Dis (2012) 1.27

Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles. Nucleic Acids Res (2004) 1.27

The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability. Hum Mol Genet (2010) 1.21

Molecular medicine for the brain: silencing of disease genes with RNA interference. Lancet Neurol (2004) 1.20

Conditional Niemann-Pick C mice demonstrate cell autonomous Purkinje cell neurodegeneration. Hum Mol Genet (2009) 1.18

Obsessive and compulsive symptoms in prediagnosed Huntington's disease. J Clin Psychiatry (2008) 1.17

Balancing act: deubiquitinating enzymes in the nervous system. Trends Neurosci (2011) 1.17

Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study. Orphanet J Rare Dis (2013) 1.15

Cellular turnover of the polyglutamine disease protein ataxin-3 is regulated by its catalytic activity. J Biol Chem (2007) 1.14

Activity and cellular functions of the deubiquitinating enzyme and polyglutamine disease protein ataxin-3 are regulated by ubiquitination at lysine 117. J Biol Chem (2010) 1.12

Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. J Clin Invest (2013) 1.12

Cognitive decline and aging: the role of concussive and subconcussive impacts. Exerc Sport Sci Rev (2012) 1.11

Histone deacetylases suppress CGG repeat-induced neurodegeneration via transcriptional silencing in models of fragile X tremor ataxia syndrome. PLoS Genet (2010) 1.11

Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease. Mol Ther (2009) 1.09

Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3. J Neurochem (2004) 1.08

Selective cochlear degeneration in mice lacking the F-box protein, Fbx2, a glycoprotein-specific ubiquitin ligase subunit. J Neurosci (2007) 1.06

Diversity in tissue expression, substrate binding, and SCF complex formation for a lectin family of ubiquitin ligases. J Biol Chem (2008) 1.05

The ubiquitin-conjugating enzyme (E2) Ube2w ubiquitinates the N terminus of substrates. J Biol Chem (2013) 1.03

Toward therapy for DYT1 dystonia: allele-specific silencing of mutant TorsinA. Ann Neurol (2003) 1.00

Understanding the role of the Josephin domain in the PolyUb binding and cleavage properties of ataxin-3. PLoS One (2010) 0.99

Technology insight: therapeutic RNA interference--how far from the neurology clinic? Nat Clin Pract Neurol (2007) 0.99

A novel route for F-box protein-mediated ubiquitination links CHIP to glycoprotein quality control. J Biol Chem (2006) 0.99

Destabilization of a non-pathological variant of ataxin-3 results in fibrillogenesis via a partially folded intermediate: a model for misfolding in polyglutamine disease. J Mol Biol (2004) 0.98

The E3 ubiquitin ligase CHIP and the molecular chaperone Hsc70 form a dynamic, tethered complex. Biochemistry (2013) 0.95

Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice. Mol Ther (2013) 0.94

Analysis of the tau-associated proteome reveals that exchange of Hsp70 for Hsp90 is involved in tau degradation. ACS Chem Biol (2012) 0.94

Degeneration of the cerebellum in Huntington's disease (HD): possible relevance for the clinical picture and potential gateway to pathological mechanisms of the disease process. Brain Pathol (2012) 0.92

Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease. Mol Ther (2013) 0.91

Splice isoforms of the polyglutamine disease protein ataxin-3 exhibit similar enzymatic yet different aggregation properties. PLoS One (2010) 0.91

Physiologic alterations in ataxia: channeling changes into novel therapies. Arch Neurol (2009) 0.90

Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease. Ann Clin Psychiatry (2008) 0.88

Caring for Machado-Joseph disease: current understanding and how to help patients. Parkinsonism Relat Disord (2009) 0.88

Early alterations of autophagy in Huntington disease-like mice. Autophagy (2010) 0.87

Splice isoform-specific suppression of the Cav2.1 variant underlying spinocerebellar ataxia type 6. Neurobiol Dis (2011) 0.86

Alzheimer's disease and environmental exposure to lead: the epidemiologic evidence and potential role of epigenetics. Curr Alzheimer Res (2012) 0.86

JosD1, a membrane-targeted deubiquitinating enzyme, is activated by ubiquitination and regulates membrane dynamics, cell motility, and endocytosis. J Biol Chem (2013) 0.85

RNA interference in neuroscience: progress and challenges. Cell Mol Neurobiol (2005) 0.84

F-box only protein 2 (Fbxo2) regulates amyloid precursor protein levels and processing. J Biol Chem (2014) 0.83

Establishment of a novel fluorescence-based method to evaluate chaperone-mediated autophagy in a single neuron. PLoS One (2012) 0.83

Transcriptional changes and developmental abnormalities in a zebrafish model of myotonic dystrophy type 1. Dis Model Mech (2013) 0.82

Ataxin-3 plays a role in mouse myogenic differentiation through regulation of integrin subunit levels. PLoS One (2010) 0.82

Compromised mitochondrial complex II in models of Machado-Joseph disease. Biochim Biophys Acta (2011) 0.82

Valosin-containing protein (VCP/p97) is an activator of wild-type ataxin-3. PLoS One (2012) 0.81

Enzymatic production of mono-ubiquitinated proteins for structural studies: The example of the Josephin domain of ataxin-3. FEBS Open Bio (2013) 0.79

C9orf72-associated FTD/ALS: when less is more. Neuron (2013) 0.77

If it's not one thing, it's another. Nat Genet (2006) 0.76

Coexistence of Huntington's disease and amyotrophic lateral sclerosis: a clinicopathologic study. Acta Neuropathol (2012) 0.76

New hope for therapy in neurodegenerative diseases. Cell Res (2013) 0.75

Drug discovery: Kill the messenger where it lives. Nature (2012) 0.75

Dangerous liaisons: polyglutamine meets HMGB. Nat Cell Biol (2007) 0.75

Considering a career in neurology research? Heed these words. Ann Neurol (2013) 0.75